Ken Griffin Cerus Corp Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Cerus Corp stock. As of the latest transaction made, Citadel Advisors LLC holds 22,500 shares of CERS stock, worth $35,550. This represents 0.0% of its overall portfolio holdings.

Number of Shares

22,500

Previous 7,200 212.5%

Holding current value

$35,550

Previous $12,000 225.0%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$1.7 - $2.39 $1.24 Million - $1.75 Million	731,366 Added 221.21%	1,061,991 $1.85 Million
Q2 2024 Aug 14, 2024	SELL	$1.62 - $2.04 $1.39 Million - $1.75 Million	-857,413 Reduced 72.17%	330,625 $581,000
Q1 2024 May 15, 2024	SELL	$1.66 - $2.42 $2.25 Million - $3.28 Million	-1,356,041 Reduced 53.3%	1,188,038 $2.25 Million
Q4 2023 Feb 14, 2024	BUY	$1.25 - $2.35 $224,806 - $422,635	179,845 Added 7.61%	2,544,079 $5.5 Million
Q3 2023 Nov 14, 2023	BUY	$1.5 - $3.07 $2.08 Million - $4.25 Million	1,385,283 Added 141.51%	2,364,234 $3.83 Million
Q2 2023 Aug 14, 2023	BUY	$1.79 - $2.9 $1.6 Million - $2.59 Million	894,394 Added 1057.74%	978,951 $2.41 Million
Q1 2023 May 15, 2023	SELL	$2.65 - $3.81 $823,556 - $1.18 Million	-310,776 Reduced 78.61%	84,557 $251,000
Q4 2022 Feb 14, 2023	BUY	$3.38 - $4.22 $526,343 - $657,151	155,723 Added 64.99%	395,333 $1.44 Million
Q3 2022 Nov 14, 2022	BUY	$3.43 - $5.83 $371,215 - $630,957	108,226 Added 82.37%	239,610 $863,000
Q2 2022 Aug 15, 2022	SELL	$4.41 - $5.69 $2.57 Million - $3.32 Million	-583,333 Reduced 81.62%	131,384 $695,000
Q1 2022 May 16, 2022	BUY	$4.81 - $6.99 $901,230 - $1.31 Million	187,366 Added 35.53%	714,717 $3.92 Million
Q4 2021 Feb 14, 2022	SELL	$5.97 - $7.93 $1.05 Million - $1.39 Million	-175,716 Reduced 24.99%	527,351 $3.59 Million
Q3 2021 Nov 15, 2021	BUY	$4.79 - $6.68 $626,393 - $873,550	130,771 Added 22.85%	703,067 $4.28 Million
Q2 2021 Aug 16, 2021	BUY	$5.35 - $6.35 $1.39 Million - $1.65 Million	260,504 Added 83.55%	572,296 $3.38 Million
Q1 2021 May 17, 2021	BUY	$5.68 - $7.87 $1.58 Million - $2.19 Million	278,091 Added 825.17%	311,792 $1.87 Million
Q4 2020 Feb 16, 2021	SELL	$5.25 - $8.56 $22,989 - $37,484	-4,379 Reduced 11.5%	33,701 $233,000
Q3 2020 Nov 16, 2020	BUY	$5.78 - $7.47 $141,453 - $182,813	24,473 Added 179.86%	38,080 $238,000
Q2 2020 Aug 14, 2020	SELL	$4.5 - $7.02 $1.15 Million - $1.79 Million	-255,376 Reduced 94.94%	13,607 $90,000
Q1 2020 May 15, 2020	SELL	$2.87 - $5.49 $3.16 Million - $6.04 Million	-1,100,721 Reduced 80.36%	268,983 $1.25 Million
Q4 2019 Feb 14, 2020	BUY	$3.84 - $4.86 $1.1 Million - $1.39 Million	285,223 Added 26.3%	1,369,704 $5.78 Million
Q3 2019 Nov 14, 2019	SELL	$4.86 - $6.05 $3.4 Million - $4.23 Million	-699,325 Reduced 39.2%	1,084,481 $5.6 Million
Q2 2019 Aug 14, 2019	BUY	$4.51 - $6.6 $7.56 Million - $11.1 Million	1,677,355 Added 1575.71%	1,783,806 $10 Million
Q1 2019 May 15, 2019	SELL	$5.16 - $6.85 $6.98 Million - $9.26 Million	-1,352,147 Reduced 92.7%	106,451 $0
Q4 2018 Feb 14, 2019	BUY	$4.89 - $7.16 $3.8 Million - $5.56 Million	776,715 Added 113.91%	1,458,598 $7.4 Million
Q3 2018 Nov 13, 2018	SELL	$6.89 - $7.78 $2.47 Million - $2.79 Million	-359,142 Reduced 34.5%	681,883 $0
Q2 2018 Aug 10, 2018	SELL	$5.19 - $7.25 $1.36 Million - $1.9 Million	-262,627 Reduced 20.15%	1,041,025 $0
Q1 2018 May 11, 2018	BUY	$3.56 - $5.74 $2.72 Million - $4.38 Million	763,704 Added 141.44%	1,303,652 $7.14 Million
Q4 2017 Feb 09, 2018	SELL	$2.76 - $3.95 $1.09 Million - $1.55 Million	-393,141 Reduced 42.13%	539,948 $1.83 Million
Q3 2017 Nov 09, 2017	BUY	$2.22 - $2.73 $2.07 Million - $2.55 Million	933,089	933,089 $2.55 Million

Others Institutions Holding CERS

# of Institutions

155

Shares Held

147M

Call Options Held

84.2K

Put Options Held

55.5K

View Full List

About CERUS CORP

Ticker CERS
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 177,090,000
Market Cap $280M
Description
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended fo...

More about CERS

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account